Bioequivalence comparison between hydroxyethyl starch 130/0.42/6: 1 and hydroxyethyl starch 130/0.4/9: 1

被引：26

作者：

Lehmann G. ^{[1
,4
]}

Marx G. ^{[2
]}

Förster H. ^{[3
]}

机构：

[1] Department of Anaesthesiology and Intensive Care Medicine, Rhoen Hospital Bad Berka, Kapellendorf

[2] Department of Anaesthesiology and Intensive Care Medicine, Friedrich-Schiller University, Jena

[3] Department of Experimental Anaesthesiology, Johann-Wolfgang Goethe University, Frankfurt

[4] Anaesthesiology and Intensive Care Medicine, Rhoen Hospital Bad Berka, 99510 Kapellendorf

来源：

Drugs in R & D | 2007年 / 8卷 / 4期

关键词：

Hydroxyethyl Starch; Plasma Viscosity; Colloid Osmotic Pressure; Hetastarch; Molar Substitution;

D O I：

10.2165/00126839-200708040-00003

中图分类号：

学科分类号：

摘要：

Objective: The aim of this study was to investigate whether a recently developed low molecular, low substituted hydroxyethyl starch (HES 130/0.42/6 : 1), altered in molar substitution and C2/C6 ratio, is bioequivalent to the former standard HES preparation (130/0.4/9 : 1). Methods: The two HES solutions were infused (60g as a single dose within 30 minutes) in healthy volunteers using a randomised, crossover design. HES serum concentrations were used for computation of pharmacokinetic parameters; area under the concentration-time curve from infusion start until 24 hours thereafter (AUC24) and maximum serum concentration (Cmax) were the primary criteria. Haemodilution, colloid osmotic pressure and plasma viscosity were measured as secondary criteria. Pentastarch (HES 200/0.5/5:1) was investigated in the same volunteers and manner during a subsequent period. Results: Using non-compartmental analysis, significant differences were found for AUC 24 (45.97 ± 8.97 mg•h/mL vs 58.32 ± 9.23 mg•h/mL; HES 130/0.42/6 : 1 vs HES 130/0.4/9 : 1) and total apparent clearance (CL; 1.14 ± 0.4 L/h vs 0.81 ± 0.34 L/h). Cmax and elimination half-life (t1/2) were similar, while the AUC 24, t1/2 and CL of pentastarch were significantly different from those of low substituted HES solutions. Conclusion: Being equivalent with pentastarch and HES 130/0.4/9 : 1 in terms of colloid osmotic and haemodilution effect, HES 130/0.42/6 : 1 shows the fastest clearance from the circulation. © 2007 Adis Data Information BV. All rights reserved.

引用

页码：229 / 240

页数：11

共 23 条

[11]

Waitzinger J., Bepperling F., Pabst G., Et al., Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification [HES (130/0.4)] after single-dose infusion of 6% or 10% solutions in healthy volunteers, Clin Drug Invest, 16, pp. 151-160, (1998)

[12]

Forster H., Physical and chemical properties of hydroxyethyl starches, Plasma volume expansion, (1992)

[13]

Yoshida M., Yamashita T., Matsuo J., Et al., Enzymic degradation of hydroxyethyl starch: Part I. Influence of the distribution of hydroxyethyl groups on the enzymic degradation of hydroxyethyl starch, Stärke, 25, (1973)

[14]

Yoshida M., Muiami Y., Kishikawa T., A study of hydroxyethyl-starch: Part III. Comparison of metabolic fates between 2-O-hydroxyethyl starch and 6-O-hydroxyethyl starch in rabbits, Staerke, 36, pp. 209-212, (1984)

[15]

Jung F., Koscielny J., Mrowietz C., Et al., The effect of molecular structure of hydroxyethyl starch on the elimination kinetics and fluidity of blood in human volunteers, Arzneimittelforschung, 43, pp. 99-105, (1993)

[16]

Treib J., Haass A., Pindur G., Et al., HES 200/0.5 is not HES 200/0.5: Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics, Thromb Haemost, 74, pp. 1452-1456, (1995)

[17]

Orth V.H., Rehm M., Haller M., Et al., The measurement of blood volume: State-of-the-art, Anaesthesist, 50, 8, pp. 562-568, (2001)

[18]

Sander O., Reinhart K., Meier-Hellmann A., Equivalence of hydroxyethyl starch HES 130/0.4 and HES 200/0.5 for perioperative volume replacement in major gynaecological surgery, Acta Anaesthesiol Scand, 47, pp. 1151-1158, (2003)

[19]

Langeron O., Doelberg M., Ang E.T., Et al., Voluven®, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5, Anesth Analg, 92, pp. 855-862, (2001)

[20]

Gallandat Huet R.C.G., Siemons A.W., Baus D., Et al., A novel hydroxyethyl starch (Voluven®) for effective perioperative plasma volume substitution in cardiac surgery, Can J Anesth, 47, pp. 1207-1215, (2000)

← 1 2 3 →